Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phospholipase A2 and small, dense low-density lipoprotein.

E Hurt-Camejo1, G Camejo, P Sartipy

  • 1Wallenberg Laboratory, Götenberg University, Sweden. Eva.Hurt@wlab.wall.gu.se

Current Opinion in Lipidology
|October 26, 2000
PubMed
Summary

High levels of small, dense low-density lipoprotein (LDL) increase cardiovascular disease risk. Secretory phospholipase A2 (sPLA2) modification of LDL enhances its atherogenic potential by promoting arterial wall interactions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.

British journal of pharmacology·2011
Same author

The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.

British journal of pharmacology·2009
Same author

Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE-related cardiovascular disease.

Scandinavian journal of rheumatology·2009
Same author

Increased lipolysis by secretory phospholipase A(2) group V of lipoproteins in diabetic dyslipidaemia.

Journal of internal medicine·2008
Same author

Reduced cholesterol accumulation by leptin deficient (ob/ob) mouse macrophages.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2006
Same author

Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes.

Journal of internal medicine·2004

Area of Science:

  • Biochemistry
  • Cardiovascular Science
  • Lipid Metabolism

Background:

  • Elevated small, dense low-density lipoprotein (LDL) is linked to cardiovascular disease (CVD).
  • Small, dense LDL exhibits increased atherogenicity compared to larger, buoyant LDL particles due to biochemical differences.

Purpose of the Study:

  • To investigate the biochemical characteristics that make small, dense LDL more atherogenic.
  • To explore the role of secretory phospholipase A2 (sPLA2) in modifying LDL and its implications for atherogenesis.

Main Methods:

  • Analysis of lipid and phospholipid content in small, dense LDL versus large, buoyant LDL.
  • Assessment of apolipoprotein B-100 conformation and proteoglycan-binding regions.
  • Evaluation of LDL interaction with proteoglycans after treatment with sPLA2.

Related Experiment Videos

  • Review of in-vivo studies on sPLA2 and atherogenesis.

    • Main Results:

    • Small, dense LDL has reduced phospholipids and unesterified cholesterol, altering apolipoprotein B-100 conformation and increasing proteoglycan-binding affinity.
    • sPLA2 treatment of LDL reduces phospholipid content, enhancing its interaction with proteoglycans.
    • Circulating sPLA2-IIA is an independent risk factor for coronary artery disease and cardiovascular events.

    Conclusions:

    • Modification of LDL by sPLA2 may generate atherogenic lipoprotein particles in vivo.
    • These modified LDL particles exhibit a high propensity for entrapment within the arterial extracellular matrix, contributing to atherogenesis.